{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:46:26Z","timestamp":1765885586606,"version":"build-2065373602"},"reference-count":101,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.medmal.2006.01.028","type":"journal-article","created":{"date-parts":[[2007,8,22]],"date-time":"2007-08-22T07:13:20Z","timestamp":1187766800000},"page":"394-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bases microbiologiques et\u00a0pharmacologiques du\u00a0traitement de\u00a0la\u00a0borr\u00e9liose de\u00a0Lyme. Traitement et\u00a0suivi de\u00a0la\u00a0phase aigu\u00eb (\u00e9ryth\u00e8me migrant)"],"prefix":"10.1016","volume":"37","author":[{"given":"M.","family":"Martinot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 33","key":"10.1016\/j.medmal.2006.01.028_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1438-4221(02)80024-8","article-title":"Standardised in vitro susceptibility testing of Borrelia\u00a0burgdorferi against well-known and newly developed antimicrobial agents: possible implications for new therapeutic approaches to Lyme disease","volume":"291","author":"Hunfeld","year":"2002","journal-title":"Int. J. Med. Microbiol."},{"issue":"3","key":"10.1016\/j.medmal.2006.01.028_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0924-8579(00)00342-3","article-title":"In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia\u00a0burgdorferi","volume":"17","author":"Hunfeld","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.medmal.2006.01.028_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jac\/48.3.447","article-title":"In vitro susceptibility of the Borrelia\u00a0burgdorferi sensu lato complex to ABT-773, a novel ketolide","volume":"48","author":"Hunfeld","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.medmal.2006.01.028_bib4","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1128\/AAC.46.11.3637-3640.2002","article-title":"Erythromycin resistance in Borrelia\u00a0burgdorferi","volume":"46","author":"Terekhova","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF01780660","article-title":"In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics","volume":"24","author":"Baradaran-Dilmaghani","year":"1996","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib6","first-page":"38","article-title":"Sensitivity of Borrelia\u00a0burgdorferi strains isolated in the Czech Republic","volume":"9","author":"Janovska","year":"2001","journal-title":"Cent. Eur. J. Public Health"},{"issue":"7","key":"10.1016\/j.medmal.2006.01.028_bib7","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.37.7.1444","article-title":"In vitro susceptibility of Borrelia\u00a0burgdorferi to 11 antimicrobial agents","volume":"37","author":"Levin","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0924-8579(00)00116-3","article-title":"Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia\u00a0burgdorferi isolates","volume":"15","author":"Hunfeld","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s100960050005","article-title":"New colorimetric microdilution method for in vitro susceptibility testing of Borrelia\u00a0burgdorferi against antimicrobial substances","volume":"19","author":"Hunfeld","year":"2000","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"10","key":"10.1016\/j.medmal.2006.01.028_bib10","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1128\/jcm.30.10.2692-2697.1992","article-title":"In vitro antimicrobial susceptibility testing of Borrelia\u00a0burgdorferi: a microdilution MIC method and time-kill studies","volume":"30","author":"Dever","year":"1992","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/1120009X.1990.11739041","article-title":"In-vitro susceptibility of Borrelia\u00a0burgdorferi and Borrelia\u00a0hermsii to ten antimicrobial agents","volume":"2","author":"Sambri","year":"1990","journal-title":"J. Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib12","first-page":"549","article-title":"Susceptibility of the Lyme disease spirochete to seven antimicrobial agents","volume":"57","author":"Johnson","year":"1984","journal-title":"Yale J. Biol. Med."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1128\/AAC.31.2.164","article-title":"In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia\u00a0burgdorferi, to four antimicrobial agents","volume":"31","author":"Johnson","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl A","key":"10.1016\/j.medmal.2006.01.028_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/25.suppl_A.33","article-title":"In vitro and in vivo susceptibility of Borrelia\u00a0burgdorferi to azithromycin","volume":"25","author":"Johnson","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.medmal.2006.01.028_bib15","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1128\/AAC.34.11.2133","article-title":"Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia\u00a0burgdorferi to cefuroxime and other antimicrobial agents","volume":"34","author":"Johnson","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02013102","article-title":"In vitro and in vivo susceptibility of Borrelia\u00a0burgdorferi","volume":"6","author":"Mursic","year":"1987","journal-title":"Eur. J. Clin. Microbiol."},{"key":"10.1016\/j.medmal.2006.01.028_bib17","first-page":"112","article-title":"European Borrelia\u00a0burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility","volume":"263","author":"Preac-Mursic","year":"1986","journal-title":"Zbl Bakt Hyg A"},{"key":"10.1016\/j.medmal.2006.01.028_bib18","first-page":"143","article-title":"Antibiotic susceptibility of Borrelia\u00a0burgdorferi in vitro and in animal models","volume":"77","author":"Wretlind","year":"1991","journal-title":"Scand. J. Infect. Dis. Suppl."},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib19","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1128\/JCM.41.4.1791-1793.2003","article-title":"In vitro susceptibility testing of four antibiotics against Borrelia\u00a0burgdorferi: a comparison of results for the three genospecies Borrelia\u00a0afzelii, Borrelia\u00a0garinii, and Borrelia burgdorferi sensu stricto","volume":"41","author":"Sicklinger","year":"2003","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijantimicag.2005.02.007","article-title":"Susceptibility of Borrelia\u00a0afzelii strains to antimicrobial agents","volume":"25","author":"Ruzic-Sabljic","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1128\/AAC.49.4.1294-1301.2005","article-title":"In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy","volume":"49","author":"Hunfeld","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2340\/0001555572297300","article-title":"Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans","volume":"72","author":"Hansen","year":"1992","journal-title":"Acta Derm. Venereol."},{"issue":"8","key":"10.1016\/j.medmal.2006.01.028_bib23","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1128\/AAC.36.8.1788","article-title":"In vitro susceptibilities of Borrelia\u00a0burgdorferi to five oral cephalosporins and ceftriaxone","volume":"36","author":"Agger","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 1","key":"10.1016\/j.medmal.2006.01.028_bib24","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1007\/BF02464959","article-title":"Roxithromycin in the treatment of Lyme disease: update and perspectives","volume":"23","author":"Gasser","year":"1995","journal-title":"Infection"},{"issue":"296S1","key":"10.1016\/j.medmal.2006.01.028_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijmm.2006.01.028","article-title":"Risk of culture-confirmed borrelial persistence in patients treated for erythema migrans and possible mechanisms of resistance","volume":"22","author":"Hunfeld","year":"2006","journal-title":"Int. J. Med. Microbiol."},{"issue":"5","key":"10.1016\/j.medmal.2006.01.028_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijantimicag.2005.11.019","article-title":"Evidence of a conjugal erythromycin resistance element in the Lyme disease spirochete Borrelia\u00a0burgdorferi","volume":"27","author":"Jackson Charlene","year":"2006","journal-title":"Intern. J. Antimicrobial Agents"},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1699-0463.1999.tb01594.x","article-title":"An in vitro study of the susceptibility of mobile and cystic forms of Borrelia\u00a0burgdorferi to metronidazole","volume":"107","author":"Brorson","year":"1999","journal-title":"APMIS"},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10123-001-0039-7","article-title":"Susceptibility of motile and cystic forms of Borrelia\u00a0burgdorferi to ranitidine bismuth citrate","volume":"4","author":"Brorson","year":"2001","journal-title":"Int. Microbiol."},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10123-002-0055-2","article-title":"An in vitro study of the susceptibility of mobile and cystic forms of Borrelia\u00a0burgdorferi to hydroxychloroquine","volume":"5","author":"Brorson","year":"2002","journal-title":"Int. Microbiol."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib30","first-page":"139","article-title":"An in vitro study of the susceptibility of mobile and cystic forms of Borrelia\u00a0burgdorferi to tinidazole","volume":"7","author":"Brorson","year":"2004","journal-title":"Int. Microbiol."},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/AAC.46.1.132-134.2002","article-title":"Efficacy of short-course ceftriaxone therapy for Borrelia\u00a0burgdorferi infection in C3H mice","volume":"46","author":"Pavia","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.medmal.2006.01.028_bib32","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1128\/AAC.40.11.2632","article-title":"In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites","volume":"40","author":"Kazragis","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.medmal.2006.01.028_bib33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1128\/AAC.38.7.1567","article-title":"Effectiveness of antimicrobial treatment against Borrelia\u00a0burgdorferi infection in mice","volume":"38","author":"Moody","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1348-0421.1997.tb01182.x","article-title":"Antibiotic treatment in mice infected with Japanese Borrelia\u00a0garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites","volume":"41","author":"Konishi","year":"1997","journal-title":"Microbiol. Immunol."},{"year":"2005","series-title":"Antibiotiques: pharmacologie et th\u00e9rapeutique: Elsevier","author":"Gaudy","key":"10.1016\/j.medmal.2006.01.028_bib35"},{"year":"2006","series-title":"The Pharmacological basis of therapeutics","author":"Goodman","key":"10.1016\/j.medmal.2006.01.028_bib36"},{"year":"1999","series-title":"Antibiotiques Agents Antibact\u00e9riens et Antifongiques: ellipses","author":"Andr\u00e9","key":"10.1016\/j.medmal.2006.01.028_bib37"},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.14.6.899","article-title":"Penetration of amoxicilline into cerebrospinal fluid","volume":"14","author":"Strausbaugh","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6A","key":"10.1016\/j.medmal.2006.01.028_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF01967830","article-title":"Pharmacokinetics and tissue concentrations of cefuroxime","volume":"12","author":"Vree","year":"1990","journal-title":"Pharm. Weekbl. Sci."},{"key":"10.1016\/j.medmal.2006.01.028_bib40","unstructured":"Philippon A, Arlet G, Schlemmer. B. B\u00eatalactamines (II). In EMC:1994. p. 1\u201328."},{"article-title":"E B-B. Tissue distribution of macrolide antibiotics","year":"1993","series-title":"Macrolides, chemistry, pharmacology and clinical uses","key":"10.1016\/j.medmal.2006.01.028_bib41"},{"issue":"3","key":"10.1016\/j.medmal.2006.01.028_bib42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.40.3.825","article-title":"Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye","volume":"40","author":"Jaruratanasirikul","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.medmal.2006.01.028_bib43","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1128\/AAC.40.5.1104","article-title":"Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis","volume":"40","author":"Karlsson","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.medmal.2006.01.028_bib44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1128\/AAC.33.7.1078","article-title":"Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis","volume":"33","author":"Dotevall","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.01.028_bib45","first-page":"74","article-title":"The use of doxycycline in nervous system Borrelia\u00a0burgdorferi infection","volume":"53","author":"Dotevall","year":"1988","journal-title":"Scand. J. Infect. Dis. Suppl."},{"issue":"11","key":"10.1016\/j.medmal.2006.01.028_bib45a","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.1989.00520470044025","article-title":"Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study","volume":"46","author":"Pfister","year":"1989","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib45b","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/infdis\/163.2.311","article-title":"Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis","volume":"163","author":"Pfister","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.01.028_bib45c","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1749-6632.1988.tb31869.x","article-title":"New chemotherapeutic approaches in the treatment of Lyme borreliosis","volume":"539","author":"Luft","year":"1988","journal-title":"Ann. N Y Acad. Sci."},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib45d","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01780643","article-title":"Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme Borreliosis","volume":"24","author":"Preac Mursic","year":"1996","journal-title":"Infection"},{"issue":"7","key":"10.1016\/j.medmal.2006.01.028_bib45e","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1128\/AAC.48.7.2697-2699.2004","article-title":"Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis","volume":"48","author":"Zeidner","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-93-1-1","article-title":"Antibiotic therapy in Lyme disease","volume":"93","author":"Steere","year":"1980","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01641422","article-title":"A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis","volume":"18","author":"Weber","year":"1990","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7326\/0003-4819-99-1-22","article-title":"Treatment of the early manifestations of Lyme disease","volume":"99","author":"Steere","year":"1983","journal-title":"Ann. Intern. Med."},{"issue":"8728","key":"10.1016\/j.medmal.2006.01.028_bib49","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/0140-6736(90)93103-V","article-title":"Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis","volume":"336","author":"Dattwyler","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01780662","article-title":"Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis","volume":"24","author":"Breier","year":"1996","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.medmal.2006.01.028_bib51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJM199707313370501","article-title":"Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease","volume":"337","author":"Dattwyler","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-117-4-273","article-title":"Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease","volume":"117","author":"Nadelman","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.medmal.2006.01.028_bib53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/AAC.39.3.661","article-title":"Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans","volume":"39","author":"Luger","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0002-9343(92)90270-L","article-title":"Treatment of early Lyme disease","volume":"92","author":"Massarotti","year":"1992","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.medmal.2006.01.028_bib55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/30.4.543","article-title":"Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin","volume":"30","author":"Strle","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF01728915","article-title":"Azithromycin versus penicillin V for the treatment of early Lyme borreliosis","volume":"21","author":"Weber","year":"1993","journal-title":"Infection"},{"issue":"9","key":"10.1016\/j.medmal.2006.01.028_bib57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/0003-4819-124-9-199605010-00002","article-title":"Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double blind, randomized, controlled trial","volume":"124","author":"Luft","year":"1996","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01710737","article-title":"Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings","volume":"21","author":"Strle","year":"1993","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.medmal.2006.01.028_bib59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s150100050069","article-title":"Comparison of azithromycin and doxycycline in the treatment of erythema migrans","volume":"28","author":"Barsic","year":"2000","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib60","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1128\/AAC.40.2.468","article-title":"Clarithromycin in treatment of early Lyme disease: a pilot study","volume":"40","author":"Dattwyler","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM200107123450207","article-title":"Lyme disease","volume":"345","author":"Steere","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"22-23","key":"10.1016\/j.medmal.2006.01.028_bib62","first-page":"916","article-title":"Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans","volume":"111","author":"Arnez","year":"1999","journal-title":"Wien Klin Wochenschr."},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib63","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1542\/peds.109.6.1173","article-title":"Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease","volume":"109","author":"Eppes","year":"2002","journal-title":"Pediatrics"},{"issue":"13-14","key":"10.1016\/j.medmal.2006.01.028_bib64","first-page":"498","article-title":"Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin","volume":"114","author":"Arnez","year":"2002","journal-title":"Wien Klin Wochenschr."},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib65","first-page":"341","article-title":"Lyme Disease and Pregnancy","volume":"53","author":"Cartter","year":"1989","journal-title":"Conn. Med."},{"key":"10.1016\/j.medmal.2006.01.028_bib66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0020-7292(92)90781-D","article-title":"Lyme disease during pregnancy","volume":"39","year":"1992","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"22-23","key":"10.1016\/j.medmal.2006.01.028_bib67","first-page":"933","article-title":"Erythema migrans in pregnancy","volume":"111","author":"Maraspin","year":"1999","journal-title":"Wien Klin. Wochenschr."},{"issue":"22-23","key":"10.1016\/j.medmal.2006.01.028_bib68","first-page":"923","article-title":"Erythema migrans in the immunocompromised host","volume":"111","author":"Maraspin","year":"1999","journal-title":"Wien Klin. Wochenschr."},{"issue":"12","key":"10.1016\/j.medmal.2006.01.028_bib69","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1086\/504384","article-title":"Erythema migrans in solid-organ transplant recipients","volume":"42","author":"Maraspin","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"13-14","key":"10.1016\/j.medmal.2006.01.028_bib70","first-page":"613","article-title":"Duration of treatment for Lyme borreliosis: time for a critical reappraisal","volume":"114","author":"Wormser","year":"2002","journal-title":"Wien Klin Wochenschr."},{"issue":"9","key":"10.1016\/j.medmal.2006.01.028_bib71","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-138-9-200305060-00005","article-title":"Duration of antibiotic therapy for early Lyme disease. A randomized, double blind, placebo-controlled trial","volume":"138","author":"Wormser","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medmal.2006.01.028_bib72","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The Clinical Assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.medmal.2006.01.028_bib73","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0934-8840(98)80128-X","article-title":"The European Union Concerted Action World Wide Web site for Lyme borreliosis","volume":"287","author":"Smith","year":"1998","journal-title":"Zentralbl. Bakteriol."},{"issue":"22-23","key":"10.1016\/j.medmal.2006.01.028_bib74","first-page":"911","article-title":"Principles of the diagnosis and antibiotic treatment of Lyme borreliosis","volume":"111","author":"Strle","year":"1999","journal-title":"Wien Klin Wochenschr."},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1517\/13543784.12.6.1003","article-title":"Current and novel therapies for Lyme disease","volume":"12","author":"Pavia","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1 Suppl","key":"10.1016\/j.medmal.2006.01.028_bib76","first-page":"S1","article-title":"Evidence-based guidelines for the management of Lyme disease","volume":"2","author":"Cameron","year":"2004","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"3","key":"10.1016\/j.medmal.2006.01.028_bib77","first-page":"454","article-title":"Lyme disease: an infectious and post-infectious syndrome","volume":"21","author":"Asch","year":"1994","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM200107123450202","article-title":"Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease","volume":"345","author":"Klempner","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.medmal.2006.01.028_bib79","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1212\/01.WNL.0000071227.23769.9E","article-title":"Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial","volume":"60","author":"Krupp","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.medmal.2006.01.028_bib80","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.283.5.609","article-title":"Long-term outcomes of persons with Lyme disease","volume":"283","author":"Seltzer","year":"2000","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.medmal.2006.01.028_bib81","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-131-12-199912210-00003","article-title":"Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease","volume":"131","author":"Shadick","year":"1999","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.medmal.2006.01.028_bib82","doi-asserted-by":"crossref","first-page":"354","DOI":"10.7326\/0003-4819-128-5-199803010-00003","article-title":"The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study","volume":"128","author":"Reid","year":"1998","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.medmal.2006.01.028_bib83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(03)00308-5","article-title":"Long-term follow-up of patients with culture-confirmed Lyme disease","volume":"115","author":"Nowakowski","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.medmal.2006.01.028_bib84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/318082","article-title":"Evaluation of Study Patients with Lyme disease, 1\u201320-year follow-up","volume":"183","author":"Kalish Robert","year":"2001","journal-title":"JID"},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib85","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-136-6-200203190-00005","article-title":"Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans","volume":"136","author":"Smith","year":"2002","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.medmal.2006.01.028_bib86","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1046\/j.1365-2133.2002.04628.x","article-title":"Long term prognosis of patients treated for erythema migrans in France","volume":"146","author":"Lipsker","year":"2002","journal-title":"Br. J. Dermatol."},{"issue":"22-23","key":"10.1016\/j.medmal.2006.01.028_bib87","first-page":"941","article-title":"The outcome of Lyme borreliosis in children","volume":"111","author":"Aberer","year":"1999","journal-title":"Wien Klin. Wochenschr."},{"issue":"17","key":"10.1016\/j.medmal.2006.01.028_bib88","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJM199610243351703","article-title":"Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group","volume":"335","author":"Gerber","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"22-23","key":"10.1016\/j.medmal.2006.01.028_bib89","first-page":"978","article-title":"The course of Lyme disease in different age groups","volume":"111","author":"Barskova","year":"1999","journal-title":"Wien Klin. Wochenschr."},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib90","first-page":"39","article-title":"Lyme borreliosis: waiting for Lyme carditis? A long-term prospective study","volume":"106","author":"Bartunek","year":"2005","journal-title":"Prague Med. Rep."},{"issue":"11","key":"10.1016\/j.medmal.2006.01.028_bib91","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/WNL.57.11.1980","article-title":"FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome","volume":"57","author":"Morgen","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.medmal.2006.01.028_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jcm.34.1.1-9.1996","article-title":"Evolution of the serologic response to Borrelia\u00a0burgdorferi in treated patients with culture-confirmed erythema migrans","volume":"34","author":"Aguero-Rosenfeld","year":"1996","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib93","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/BF01713052","article-title":"Lyme borreliosis: problems of serological diagnosis","volume":"24","author":"Hofmann","year":"1996","journal-title":"Infection"},{"issue":"6","key":"10.1016\/j.medmal.2006.01.028_bib94","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/jcm.32.6.1519-1525.1994","article-title":"Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis","volume":"32","author":"Hammers-Berggren","year":"1994","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.medmal.2006.01.028_bib95","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/clind\/15.5.788","article-title":"Persistence of serum antibodies to Borrelia\u00a0burgdorferi in patients treated for Lyme disease","volume":"15","author":"Feder","year":"1992","journal-title":"Clin. Infect. Dis."},{"issue":"22","key":"10.1016\/j.medmal.2006.01.028_bib96","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM198812013192203","article-title":"Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia\u00a0burgdorferi","volume":"319","author":"Dattwyler","year":"1988","journal-title":"N. Engl. J. Med."}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X07000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X07000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:04:21Z","timestamp":1759971861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X07000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":101,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0399077X07000704"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2006.01.028","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bases microbiologiques et\u00a0pharmacologiques du\u00a0traitement de\u00a0la\u00a0borr\u00e9liose de\u00a0Lyme. Traitement et\u00a0suivi de\u00a0la\u00a0phase aigu\u00eb (\u00e9ryth\u00e8me migrant)","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2006.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}